Efficiency of coronary heart disease standard therapy in combination with nikorandil in patients with angina. Study of the correlation of endothelial dysfunction with data of laboratory and instrumental investigations

Cover Page

Cite item

Full Text

Abstract

We investigated the association of indicators of endothelial dysfunction (ED) in patients with angina pectoris with the data of laboratory and instrumental studies - clinical indicators of current angina, myocardial remodeling processes, pro - inflammatory markers and blood lipids. Also evaluated antiischemic, antianginal, cardioprotective, endothelioprotective and antiatherosclerotic efficiency of standard therapy of coronary heart disease (CHD) compared with a combination of CHD standard therapy with the drug of group of potassium channel activators nikorandil in patients with II-III angina functional class in long - term administration. Results of the study indicate a significant correlation between ED performance indicators and the number and duration of episodes of myocardial ischemia, some myocardial morphofunctional parameters, lipid profile and inflammatory markers. The inclusion of nicorandil into the standard therapy of CHD leads to more significant changes in the ED parameters and atherogenesis, clinical evaluation of angina pectoris, myocardial remodeling processes, pro-inflammatory factors.

About the authors

Yu. A Solodova

Kuban State Medical University of the Ministry of Health of the Russian Federation

Email: proped.kgmu@mail.ru
ассистент каф. пропедевтики внутренних болезней ГБОУ ВПО КубГМУ 350063, Russian Federation, Krasnodar, ul. Sedina, d. 4

A. S Adamchik

Kuban State Medical University of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., зав. каф. пропедевтики внутренних болезней ГБОУ ВПО КубГМУ 350063, Russian Federation, Krasnodar, ul. Sedina, d. 4

References

  1. Roger V.L et al. Heart disease and stroke statistics-2012 update a report from the American heart association. Circulation 2012; 125 (1): e2-e220.
  2. Lloyd-Jones D et al. Heart disease and stroke statistics-2010 update a report from the American Heart Association. Circulation 2010; 121 (7): e46-e215.
  3. Tarkin J.M, Kaski J.C. Pharmacological treatment of chronic stable angina pectoris. Clin Med 2013; 13 (1): 63-70.
  4. Choi B.J et al. Coronary endothelial dysfunction is associated with inflammation and vasa vasorum proliferation in patients with early atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology 2014; 34 (11): 2473-7.
  5. Li J.J, Fang C.H. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses 2004; 62 (4): 499-506.
  6. Dzemali O et al. Surgical left ventricular remodeling leads to better long - term survival and exercise tolerance than coronary artery bypass grafting alone in patients with moderate ischemic cardiomyopathy. J Thoracic Cardiovasc Surg 2009; 138 (3): 663-8.
  7. Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J 2013; 34 (38): 2949-3003.
  8. Gayet J.L, Paganelli F, Cohen-Solal A. Update on the medical treatment of stable angina. Arch Cardiovasc Dis 2011; 104 (10): 536-44.
  9. Ahmed L.A et al. Pharmacological preconditioning with nicorandil and pioglitazone attenuates myocardial ischemia/reperfusion injury in rats. Eur J Pharm 2011; 663 (1): 51-8.
  10. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359 (9314): 1269-75.
  11. Izumiya Y, Kojima S, Kojima S et al. Long - term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris. Atherosclerosis 2011; 214 (2): 415-21.
  12. Кухарчук В.В., Сергиенко И.В., Семенова А.Е. Возможные механизмы стабилизации антеросклеротической бляшки на фоне терапии розувастатином. Атеросклероз и дислипидемии. 2010; 1.
  13. Sekiya M, Sato M, Funada J et al. Effects of the long - term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol 2005; 46: 63-7.
  14. Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin in older patients with systolic heart failure. New Eng J Med 2007; 357 (22): 2248-61.
  15. Комаров А.Л., Панченко Е.П. Частота поражений различных сосудистых бассейнов и медикаментозное лечение больных с высоким риском атеротромботических осложнений. Российские результаты международного исследования AGATHA. Кардиология. 2004; 11: 39-44.
  16. Панченко Е.П., Добровольский А.Б., Довлатов К.К. Факторы риска сердечно - сосудистых заболеваний и подходы к их коррекции в начале XXI века (по материалам регистра REACH). Кардиоваскулярная терапия и профилактика. 2006; 5 (6): 91-4.
  17. Загидуллин Н.Ш. и др. Значение дисфункции эндотелия при сердечно - сосудистых заболеваниях и методы ее медикаментозной коррекции. Кардиология. 2010; 5: 54-60.
  18. Беленков Ю.Н. Ремоделирование левого желудочка: комплексный подход. Сердечная недостаточность. 2002; 4 (14): 161-3.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).